Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+]i increase in cultured neuroblastoma cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 3, 2003, Pages 205-215

  Hong, Show Jen ^a   Wu, Kwou Yeung ^a   Wang, Hwei Zu ^a   Fong, Jim C ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CALCIUM; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; FURA 2 ACETOXYMETHYL ESTER; GLUTAMIC ACID; LATANOPROST; PILOCARPINE; PRESERVATIVE; SPERSACARPINE; TIMOLOL MALEATE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; SPECTROFLUOROMETRY;

EID: 0038651238     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803321908338     Document Type: Article

References (37)

1. Ding, J.M., Buchanan, G.F., Tischkau, S.A., Chen, D., Kuriashkina, L., Faiman, L.E., Alster, J.M., McPherson, P.S., Campbell, K.P., and Gillette, M.U. A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock. Nature 394:381-384, 1998.
2. Mintz, E.M., and Albers, H.E. Microinjection of NMDA into the SCN region mimics the phase shifting effects of light in hamster. Brain Res. 758:245-249, 1997.
3. Saber, J.L., Deemer, J.L., and Starkman, S. Emerging therapies for ischemic stroke. Am. J. Ophthalmol. 124:384-393, 1997.
4. Dreyer, E.B., Zurakowski, D., Schumer, R.A. Podos, S.M., and Lipton, S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmolol. 114:299-305, 1996.
5. +. Mol. Pharmacol. 56:619-623, 1999.
6. ++ channels in isolated rat neurons. J. Pharmacol. Exp. Ther. 286:201-214, 1998.
7. 2+ changes in rat forebrain-neurons. J. Physiol. Lond. 509:103-116, 1998.
8. 2+ rises and consequent oxygen radical production. J. Neurosci. 18:7727-7738, 1998.
9. Thayer, S.A., Murphy, S.N., and Miller, R.J. Widespread distribution of dihydropyridine-sensitive calcium channels in the central nervous system. Mol. Pharmacol. 30:505-509, 1986.
10. Deshpande, J.K., Siesjo, B.K., and Wieloch, T. Calcium accumulation and neuronal damage in the rat hippocampus following cerebral ischemia. J. Cereb. Blood Flow Metab. 7:89-95, 1987.
11. Martins E, Inamura K. Themner K, Malmquist KG, and Siesjo BK. Accumulation of calcium and loss of potassium in the hippocampus following transient cerebral ischemia: a potent microprobe study. J. Cereb. Blood Flow Metab. 8:531-538, 1988.
12. Siesjo BK, and Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression; a unifying hypothesis. J. Cereb. Blood Flow Metab. 9:127-140, 1989.
13. Coleman, AL. Glaucoma. Lancet 354:1803-1810, 1999.
14. Brubaker, R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 12:473-483, 1996.
15. 2-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 296:216-223, 2001.
16. Osborne, N.N., DeSantis, L., Bae, J.H., Ugarte, M., Wood, J.P., Nash, M.S., and Chidlow, G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 69:331-342, 1999.
17. 2+ mobility in cultured H9c2 myocardiac ventricular cells. Cell Signal. 14:811-817, 2002.
18. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450, 1985.
19. Marsden, P.A., Danthuluri, N.R., Brenner, B.M., Ballermann, B.J., and Brock, T.A. Endothelin action on vascular smooth muscle involves inositol triphosphate and calcium mobilization. Biochem. Biophys. Res. Commun. 158:86-93, 1989.
20. Taylor, C.W. Receptor regulation of calcium entry. Trends Pharmacol. Sci. 8:79-80, 1987.
21. Seubert, P., Nakagawa, Y., Ivy, G., Vanderklish, P., Baudery, M., and Lynch, G. Intrahippocampal colchicine injection results in spectrin proteolysis. Neuroscience 31:195-202, 1989.
22. Lee, K.S., Frank, S., Vanderklish, P., Arai, A., and Lynch, G. Inhibition or proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. USA 88:7233-7237, 1991.
23. Kristian, T., and Siesjo, B.K. Calcium in ischemic cell death. Stroke 29:705-718, 1998.
24. Lipton, S.A., and Nicotera, P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 23:165-171, 1998.
25. Siesjo, B.K. A new perspective on ischemic brain damage? Prog. Brain Res. 96:1-9, 1993.
26. Brandstatter, J.H., Hartveit, E., Sassoe-Pognetto, M. and Wassle, H. Expression of NMDA and high-affinity kainite receptor subunit mRNAs in the rat retina. Eur. J. Neurosci. 6:1100-1112, 1994.
27. Buckley, M.M., Goa, K.L., and Clissold, S.P. Ocular betaxolol. A review of its pharmacological properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 40:75-90, 1990.
28. Hester, R.K., Chen, Z., Becker, E.J., McLaughlin, M., and DeSantis, L. The direct vascular relaxing action of betaxolol, carteolol and timolol in porcine long posterior ciliary artery. Surv. Ophthalmol. 38:125-134, 1994.
29. Hoste, A.M., and Sys, S.U. The relaxant action of betaxolol on isolated bovine retinal microarteries. Curr. Eye Res. 13:483-487, 1994.
30. Melena, J., Stanton, D., and Osborne, N.N. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch. Clin. Exp. Ophthalmol. 239:522-530, 2001.
31. Osborne, N.N., Chidlow, G., Nash, M.S., and Wood, J.P.M. The potential of neuroprotection in glaucoma treatment. Curr. Op. Ophthalmol. 10:82-92, 1999.
32. Osborne, N.N., Cazevieille, C., Carvalho, A.L., Larsen, A.K., and DeSants, L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751:113-123, 1997.
33. Burke, J., and Schwartz, M. Preclinical evaluation of brimonidine. Surv. Ophthalmol. 41:9-18, 1996.
34. Groh, M.J., Michelson, G., Harazny, J., Groh, M., and Koschinsky, K. Changes in retinal blood flow by topical administration of 0.1% dipivefrin. Ophthalmology 96:706-710, 1999.
35. Brooks, A.M., and Gillies, W.E. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 2:208-221, 1992.
36. Gross, R.L., Hensley, S.H., Gao, F., and Wu, S.M. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of beta-blocker. Surv. Ophthalmol. 43:162-170, 1999.
37. Hester, R.K., Chen, Z., Becker, E.J., McLaughlin, M., and DeSantis, L. The direct vascular relaxing action of betaxolol, carteolol and timolol in porcine long posterior ciliary artery. Surv. Ophthalmol. 38:125-134, 1994.